Fast Track

You have full text access to this OnlineOpen article

A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk

  1. Peter Krippl1,†,*,
  2. Uwe Langsenlehner1,
  3. Wilfried Renner2,
  4. Babak Yazdani-Biuki2,
  5. Gerald Wolf3,
  6. Thomas C. Wascher2,
  7. Bernhard Paulweber4,
  8. Josef Haas5,
  9. Hellmut Samonigg1

Article first published online: 30 MAY 2003

DOI: 10.1002/ijc.11238

Issue

International Journal of Cancer

International Journal of Cancer

Volume 106, Issue 4, pages 468–471, 10 September 2003

Additional Information

How to Cite

Krippl, P., Langsenlehner, U., Renner, W., Yazdani-Biuki, B., Wolf, G., Wascher, T. C., Paulweber, B., Haas, J. and Samonigg, H. (2003), A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer, 106: 468–471. doi: 10.1002/ijc.11238

Author Information

  1. 1

    Department of Internal Medicine, Division of Oncology, Karl-Franzens University Graz, Austria

  2. 2

    Department of Internal Medicine, Karl-Franzens University Graz, Austria

  3. 3

    Department of Radiology, Division of Nuclear Medicine, Karl-Franzens University Graz, Graz, Austria

  4. 4

    Department of Internal Medicine, Landeskrankenanstalten Salzburg, Austria

  5. 5

    Department of Obstetrics and Gynecology, Karl-Franzens University Graz, Austria

  1. †

    Fax +43-316-385-3355

*Klinische Abteilung für Onkologie, Medizinische Universitätsklinik Graz, Auenbruggerplatz 15, A-8036 Graz, Austria

Publication History

  1. Issue published online: 1 JUL 2003
  2. Article first published online: 30 MAY 2003
  3. Manuscript Accepted: 10 APR 2003
  4. Manuscript Revised: 28 JAN 2003
  5. Manuscript Received: 23 SEP 2002

Funded by

  • Austrian Cancer Aid/Styria. Grant Number: 02/2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

REFERENCES

  • 1
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7.
    Direct Link:
  • 2
    RiesLAG, KosaryCL, HankeyBF, eds. SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute, 1999.
  • 3
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–59.
  • 4
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347: 1713–27.
  • 5
    Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346: 883–7.
  • 6
    Kelsey JL. Breast cancer epidemiology: summary and future directions. Epidemiol Rev 1993; 15: 256–63.
  • 7
    World Cancer Research Fund—American Institute of Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Mebasha USA: Banta Book Group, 1997. S.252.
  • 8
    Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001; 21: 1–18.
    Direct Link:
  • 9
    Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89: 51–62.
    Direct Link:
  • 10
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57.
  • 11
    Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443–8.
  • 12
    Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28: 178–83.
  • 13
    Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635–9.
  • 14
    Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci Colch 1998; 94: 395–404
  • 15
    Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998; 275: H1054–061.
  • 16
    Hu YF, Luscher B, Admon A, Mermod N, Tjian R. Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev 1990; 4: 1741–52.
  • 17
    Mermod N, Williams TJ, Tjian R. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988; 332: 557–61.
  • 18
    Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002; 22: 1058–61.
View Full Article (HTML) Get PDF (81K)